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Abstract
Background: HPV type distribution by cytological status represents useful information to predict the impact of
mass vaccination on screening programs.
Methods: women aged from 25 to 64 who attended cervical cancer screening in five different Italian regions were
tested for HPV infection with Hybrid Capture II (HCII) low and high risk probes. Women repeating Pap-test upon
unsatisfactory or positive results, or as a post-treatment and post-colposcopy follow-up analysis, were excluded
from our study. High risk (HR) HPV positive samples were typed using GP5+/GP6+ primed PCR, followed by
Reverse Line Blot for 18 high/intermediate risk HPV types, while low risk (LR) HPV positive samples were tested
with type specific primers for HPV6 and HPV11.
Results: 3410 women had a valid HCII and Pap-test. The prevalence of HR and LR infections was 7.0% and 3.6%,
29.1% and 13.7%, 68.1% and 31.9%, 60.0% and 0.0%, 65.0% and 12.0%, for negative, ASC-US, L-SIL, ASC-H and H-SIL
cytology, respectively. The fraction of ASC-US+ cytology due to HPV 16 and 18 ranged from 11.2 (HPV 16/18 alone)
to 15.4% (including HPV 16/18 in co-infection with other virus strains), and that due to HPV 6 and 11 ranged from
0.2% (HPV 6/11 alone) to 0.7% (including HPV 6/11 in co-infection with other LR virus strains).
Conclusions: mass vaccination with bivalent or quadrivalent HPV vaccine would modestly impact on prevalence of
abnormal Pap-test in screening.
Background
In Italy, vaccination against HPV was included in the
routine vaccination schedule at the beginning of 2008
and has since been actively offered to all 11-year old
girls [1].
Since 2006, both the Ministry of Health and the Cen-
tre for Disease Prevention and Control have planned
and commissioned a set of studies to assess HPV epide-
miology before introducing the vaccine and to predict
the impact of a mass vaccination campaign [2].
In particular, the aim of the present study was to mea-
sure the prevalence of different HPV types in the
general population attending screening programs in the
metropolitan area of Rome and southern Italy.
Here, we report the proportion of HPV types by cyto-
logical status. We calculated the proportion of abnormal
cytology attributable to HPV 16-18 and 6-11 infection.
Methods
Setting
The study was conducted within cervical cancer screening
programs that actively invite the entire target population
(age ranging from 25 to 64) in Rome and southern Italy.
A convenience sample of the existing screening programs
was selected, because the study needed active participation
to the local screening programs and formal approval from
the Local Health Unit director. Nevertheless, our final
sample included most of the well established programs in
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5 different regions: Abruzzo, Campania, Lazio, Sardinia,
and Sicily. The planned sample size was 4000 women, 800
for each region. The structure and the statistical power of
our sample have already been described in detail elsewhere
[3]. The recruitment was conducted between December
2007 and September 2008.
Sample collection
Cervical scrape samples were collected in ThinPrep vials
containing PreservCyt (Cytyc Corp., Marlborough, USA)
transport medium or in Specimens Transport Medium
(STM) (DNAPAP cervical sampler, Qiagen, Gaithers-
burg, USA). Before testing, 400 μl of STM samples, vor-
texed on a shaking platform at 1000 rpm for at least
10 minutes, were biobanked at -80°C for typing proce-
dures in case of HCII positivity. Only in one centre
(Roma G., recruiting 400 women), the primary screening
test was HPV, consequently data from this centre were
not informative for this study.
Cytological interpretation
The cytology was interpreted locally at each centre
according to the Bethesda 2001 system (TBS2001) [4].
We grouped our results into four classes: negative
(including benign cellular changes), ASC-US (including
A G C ) ,L - S I L ,A S C - H ,a n dH - S I Lo rm o r es e v e r es a m -
ples (including invasive squamous carcinoma, adenocar-
cinoma in situ). In two centres, pathologists reported
also benign cellular changes or other reactive cellular
abnormalities that refer to the previous classifications.
In any case, these women were all referred to normal
screening interval (i.e. three years) and were included in
the negative cytology class.
All screening pathology units participate in routine
quality control programs based on the circulation of
standard slide sets [5].
HPV testing and typing
The molecular biology methods have been described in
detail elsewhere (3). Here we briefly report the adopted
typing strategies.
The presence of high risk (HR) and low risk (LR) HPVs
in cervical specimens was evaluated by Hybrid Capture
II
® ( H C I I )( Q i a g e n ,G a i t h e r s b u r g ,U S A )( 1 2 ,1 3 ,1 4 ,1 5 ,
16, 17) using probemix B, specific for 13 HR HPV types:
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68, and
probemix A, specific for 5 LR HPV types: 6, 11, 42, 43
and 44 [6]. The standard 1 pg/ml HPV DNA positivity
threshold was adopted. HPV DNA testing was performed
locally in 4 sites (one in Abruzzo, one in Campania and
two in Rome) while samples collected in Cagliari and
Catania were analysed in Florence (ISPO).
Typing procedures were centralized in Florence at the
ISPO laboratory and all centres involved in the study
sent HR or LR HPV positive samples there. The types
included in IARC group 1 and 2a were classified as HR
strains, the other types as LR ones [7].
DNA was extracted from 1.5 ml of samples in Preserv-
Cyt
® solution and 200 μl of STM samples using
QIAamp DNAMini Kit.
HCII HR HPV positive specimens were amplified and
typed with “consensus High Risk HPV genotyping kit”
(Qiagen), a system based on PCR with biotinylated GP5
+/GP6+ primers [8], followed by reverse Line Blot for
18 HR HPV types: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52,
53, 56, 58, 59, 66, 68, 73 and 82.
GP5+/6+PCR-negative and reverse Line Blot-negative
samples were amplified for the b-globin gene using
GH20-PC04 primers (268 bp amplicon lenght) to assess
the integrity of DNA [9].
b-globin positive samples were re-typed with “INNO-
LiPA HPV genotyping Extra Amp” (Innogenetics, Ghant,
Belgium) following the manufacturer’s instructions. This
system targets 28 HR or LR HPV types: 6, 11, 16, 18, 26,
31, 33, 35, 39, 40, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66,
68, 69, 70, 71, 73, 74 and 82. b-globin negative samples
were extracted and typed again.
The remaining un-typed samples (GP5+/6+PCR-
positive, reverse Line Blot-negative and INNO-LiPA
negative) were considered untyped HPV (HPV X).
HCII LR HPV positive specimens were typed using
HPV6 and HPV11 specific primers [10]. No LR type,
other than 6 and 11, was searched for.
Analysis
The prevalences of HR and LR HPV types by cytological
class are reported. The proportion of HPV 16-18 and
HPV 6-11-16-18 by cytological class are reported,
including and excluding cases with co-infection of other
HPV types. All analyses were performed separately for
women under 35.
Co-infections of vaccine types with other types not
included in vaccines are classified as follows: for HR
vaccine types, HPV 16-18 alone (16, 18 or 16+18), HPV
16-18 + HR (HPV 16-18 + any non-vaccine high risk
type independently from the presence of LR types),
HPV 16-18 + LR (HPV 16-18 + any LR types, but with-
out any co-infection of non-vaccine HR). Similarly, for
LR vaccine types, HPV 6-11 alone (6, 11 or 6+11), HPV
6-11 + HR (HPV 6-11 + any non-vaccine high risk type,
i.e. excluding 16-18, independently from the presence of
other LR types), HPV 6-11 + LR (HPV 6-11 + any LR
types, excluding any co-infection with HR types).
We estimated the age-adjusted Population Attributa-
ble Risk of Cytology abnormalities due to HPV vaccine
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proposed by Fleiss [11], while 95% confidence intervals
were computed according to the algorithm proposed by
Rothman [12].
The analysis was performed taking into account the
two stage sample using STATA 8 survey module [13].
Ethics
The study was approved by the Ethics Committee of the
Istituto Superiore di Sanità (the Italian National Institute
of Health, CE-ISS 07-162 e 07/163). Women were
informed of an additional HPV test in the screening
procedure and asked to sign a consent form.
Results
Table 1 reports the distribution of cytology results by
recruiting centre. The proportion of inadequate samples
ranges from 0 to 2.4%, while the proportion of ASC-
US+ cytology ranges from 3.4% to 12.5%.
Table 2 reports the HPV types found by cytology
class. The overall positivity of HR types increases with
cytology severity. HPV 16 is the most frequent virus
strain in all classes, its frequency is higher in ASC-H
and H-SIL (50% and 37%, respectively) than in ASC-US
and L-SIL (7% and 22%, respectively). HPV 18 is rare in
a l lc l a s s e s( 0 . 3 %i nn o r m a l ,0 . 4i nA S C - U S ,4 . 2i nL - S I L
and 0 in ASC-H and H-SIL). HPV 6 and 11 were not
found in ASC-H and H-SIL and are present only in
3.5% and 5.6% of ASC-US and L-SIL samples,
respectively.
Prevalence of HR infections is double in women with
inadequate cytology as compared to that observed in
women with negative cytology.
Table 3 shows the fraction of cytologic abnormalities
in the population attributable to HPV 16-18 and HPV
6-11 infections alone, in co-infection with other HR
types or in co-infections with only LR types. The sum of
fraction attributable to HPV 16-18 alone and in co-
infection with LR types is 12.1% and 20.6% for ASC-
US+ and L-SIL+, respectively. The proportion rises to
15.4% and 28% for ASC-US+ and L-SIL+, respectively, if
we include also co-infections with other HR types. The
inclusion of HPV6 and 11 adds 0.7% to the attributable
fraction of the ASC-US cytology and has no effect on
the L-SIL+ cytology.
In women younger than 35, the HPV16-18 attributable
fraction is slightly higher, even if not significantly: 14.6%
and 21.2% for ASC-US+ and L-SIL+, respectively includ-
ing only LR co-infections; 19.7% and 30.3% for ASC-
US+ and L-SIL+, respectively, if we also include co-infec-
tions with other HR types. The inclusion of HPV 6 and
11 adds 1.9% to the attributable fraction of the ASC-US
cytology and has no effect on the L-SIL+ cytology.
Discussion
HPV prevalence
The overall HPV prevalence found in this study was
similar to other Italian population-based studies [14,15].
A detailed discussion about type specific HPV preva-
lence in Central and Southern Italy based mostly on
these data was presented elsewhere (3). Here, we report
the results of HPV typing by cytology class, a piece of
information that was not available at the time of the
above mentioned publication.
While, as expected, the prevalence of HR infections
increases with cytology severity, it is worth underlining
that HR HPV prevalence is double in inadequate sam-
ples as compared to negative ones. A cost effectiveness
analysis of a possible use of HPV DNA test [16] com-
pared to repeated cytology should be performed, parti-
cularly taking into account the very low compliance
with repeated cytology, i.e. about 60% [17].
The HPV prevalence in general population is quite
low in Italy compared to other countries. More surpris-
ingly, the observed low prevalence persists in all cytol-
ogy classes, compared to other studies [18-20]. There
are two possible explanations for the low prevalence of
HPV infections in cytological abnormalities: 1) the
Table 1 Distribution of cytology results by recruiting centre
Lazio Campania Abruzzo Sicily Sardinia All
N%N %N%N%N% N %
Negative 385 95.8 673 94.3 734 91.8 731 94.2 628 87.5 3151 92.4
Positive 14 3.5 24 3.4 48 6.0 31 4.0 90 12.5 210 6.2
ASC-US 6 1.5 11 1.5 26 3.3 22 2.8 49 6.8 117 3.4
AGC 0 0.0 1 0.1 0 0.0 1 0.1 1 0.1 3 0.1
L-SIL 5 1.2 11 1.5 14 1.8 6 0.8 36 5.0 72 2.1
ASC-H 0 0.0 0 0.0 7 0.9 0 0.0 3 0.4 10 0.3
H-SIL 3 0.7 1 0.1 1 0.1 2 0.3 1 0.1 8 0.2
Inadequte 3 0.7 17 2.4 18 2.3 14 1.8 0 0.0 52 1.5
All 402 714 800 776 718 3410
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Negative ASC-US* L-SIL ASC-H H-SIL Inadequate All
N% N% N % N % N %N % N%
3151 117 100.0 72 100.0 10 100.0 8 100 52 100 3410 100
age
25-34 690 21.9 36 30.8 37 51.4 3 30.0 1 12.5 18 34.6 785 23.0
35-44 1071 34.0 50 42.7 21 29.2 3 30.0 4 50.0 15 28.8 1164 34.1
45-54 962 30.5 26 22.2 13 18.1 4 40.0 2 25.0 16 30.8 1023 30.0
55-64 428 13.6 5 4.3 1 1.4 0 0.0 1 12.5 3 5.8 438 12.8
Hybrid capture
HR+ only 195 6.2 24 20.5 30 41.7 6 60.0 5 62.5 8 15.4 268 7.9
LR+ only 85 2.7 6 5.1 4 5.6 0 0.0 0 0.0 2 3.8 97 2.8
HR & LR+ 27 0.9 10 8.5 19 26.4 0 0.0 1 12.5 0 0.0 57 1.7
Total 307 9.7 40 34.2 53 73.6 6 60.0 6 75.0 10 19.2 422 12.4
Types
6 19 0.6 3 2.6 2 2.8 0 0.0 0 0.0 0 0.0 24 0.7
11 6 0.2 1 0.9 2 2.8 0 0.0 0 0.0 0 0.0 9 0.3
16 67 2.1 9 7.7 16 22.2 5 50.0 3 37.5 2 3.8 100 2.9
18 11 0.3 0 0.0 3 4.2 0 0.0 0 0.0 1 1.9 14 0.4
26 1 0.0 0 0.0 1 1.4 0 0.0 0 0.0 0 0.0 2 0.1
31 26 0.8 2 1.7 6 8.3 0 0.0 1 12.5 0 0.0 35 1.0
33 12 0.4 1 0.9 4 5.6 0 0.0 0 0.0 0 0.0 17 0.5
35 10 0.3 3 2.6 1 1.4 0 0.0 2 25.0 1 1.9 16 0.5
39 10 0.3 4 3.4 1 1.4 0 0.0 0 0.0 1 1.9 15 0.4
40 4 0.1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 0.1
42 7 0.2 1 0.9 1 1.4 0 0.0 0 0.0 0 0.0 9 0.3
43 3 0.1 2 1.7 0 0.0 0 0.0 0 0.0 0 0.0 5 0.1
44 0 0.0 1 0.9 0 0.0 0 0.0 0 0.0 0 0.0 1 0.0
45 11 0.3 2 1.7 0 0.0 0 0.0 0 0.0 0 0.0 13 0.4
51 18 0.6 2 1.7 9 12.5 0 0.0 0 0.0 1 1.9 29 0.9
52 15 0.5 2 1.7 2 2.8 0 0.0 0 0.0 1 1.9 19 0.6
53 9 0.3 3 2.6 7 9.7 0 0.0 0 0.0 1 1.9 19 0.6
54 2 0.1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 0.1
56 14 0.4 2 1.7 6 8.3 0 0.0 0 0.0 0 0.0 22 0.6
58 14 0.4 2 1.7 2 2.8 0 0.0 1 12.5 0 0.0 19 0.6
59 12 0.4 1 0.9 1 1.4 0 0.0 0 0.0 0 0.0 14 0.4
66 15 0.5 2 1.7 6 8.3 0 0.0 1 12.5 0 0.0 24 0.7
68 9 0.3 0 0.0 2 2.8 0 0.0 0 0.0 0 0.0 11 0.3
70 4 0.1 1 0.9 0 0.0 0 0.0 0 0.0 0 0.0 5 0.1
73 5 0.2 0 0.0 0 0.0 1 10.0 0 0.0 0 0.0 6 0.2
81 3 0.1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 3 0.1
82 2 0.1 1 0.9 1 1.4 0 0.0 0 0.0 0 0.0 4 0.1
co-infections HR+
2 53 1.7 8 6.8 16 22.2 0 0.0 2 25.0 0 0.0 79 2.3
3 13 0.4 1 0.9 3 4.2 0 0.0 0 0.0 0 0.0 17 0.5
4 1 0.0 0 0.0 1 1.4 0 0.0 0 0.0 0 0.0 2 0.1
HR: high risk; LR: low risk (7).
* Including 3 Atypical Glandular Cells (AGC), only one positive for HPV 16.
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grams may be sub-optimal and consequently our data
cannot be generalised to other screening programs in
similar conditions; 2) the low prevalence of infections
may contribute to a low positive predictive value of
cytology for infection itself. The two hypotheses are not
mutually exclusive. Whatever the reason, in Italy it
could be useful to perform a triage test with HPV DNA
not only for ASC-US+ samples but also for L-SIL in
women over 35, as previously showed by Ronco and col-
laborators [21].
In all cytology classes HPV 16 is the most prevalent
type and, overall, its prevalence is more than twice the
prevalence of the type ranking second, HPV31. Never-
theless, the proportion of cytological abnormalities rea-
sonably due to HPV 16 or 18 is negligible for ASC-US,
moderate for L-SIL and relevant only for ASC-H and
H-SIL, even if for these two last cytological classes our
estimates are based on few observations and cannot be
accurate. Given the relative frequency of cytology classes
in the screening population, the overall impact on
screening program positivity rate of a bivalent vaccine
(16-18) would be 12-15% and that of a quadrivalent vac-
cine (6-11-16-18) would be 13-16%. A modest effect
compared to the variability observed among different
programs or to what would be obtained with a triage
test strategy for ASC-US samples, still scarcely imple-
mented in Italian screening programs.
Furthermore, we must take into account that reduc-
tion in prevalence will probably increase the proportion
of false positives, i.e. a decrease of Pap-test Positive Pre-
dictive Value for low grade lesions [22]. Consequently,
the decrease in ASC-US and L-SIL prevalence will not
be translated into an equal decrease in screening pro-
grams positivity rate.
Actually, the targets of mass vaccination are pre-
adolescent girls and screening programs will see the vacci-
nated cohorts when these girls are 25. Even if we consider
Table 3 Fraction of cytology abnormalities in the population attributable to HPV 16-18 and HPV 6-11 alone and in co-
infection with high and low risk types (7)
ALL PAP TEST RESULTS
Negative ASC-US L-SIL+
3151 117 90
HPV INFECTION N % N % N % PAR ASC-US+ (95% CI) PAR L-SIL+ (95% CI)
HPV negative 2844 90.3 77 65.8 25 27.8
16-18 alone 43 1.4 8 6.8 17 18.9 11.2 (6.6-15.7) 18.4 (9.8-26.1)
16-18 & other HR+ 28 0.9 1 0.9 7 7.8 3.3 (0.5-6.0) 7.4 (1.7-12.8)
16-18 & LR+ 3 0.1 0 0.0 2 2.2 0.9 (0.0-2.2) 2.2 (0.0-5.2)
6-11 alone 17 0.5 1 0.9 0 0.0 0.2 (0.0-1.1)
6-11 & HR+ (excluded 16-18) 2 0.1 1 0.9 2 2.2 1.4 (0.2-3.0) 2.2 (0.0-5.2)
6-11 & other LR+ 1 0.0 1 0.9 0 0.0 0.5 (0.5-1.4)
other HR+ only 142 4.5 22 18.8 32 35.6 23.4 (16.5-29.6) 33.9 (22.9-43.4)
other LR+ only 63 2.0 5 4.3 3 3.3 2.7 (0.0-5.5) 2.7 (0.0-6.4)
other HR+ & LR+ 8 0.3 1 0.9 2 2.2 1.3 (0.0-2.9) 2.1 (0.0-5.1)




HPV INFECTION N % N % N % PAR ASC-US+ (95% CI) PAR L-SIL+ (95% CI)
HPV negative 649 84.2 22 52.4 9 22.0
16-18 alone 19 2.5 4 9.5 8 19.5 13.4 (5.3-20.8) 18.8 (5.6-30.2)
16-18 & other HR+ 17 2.2 1 2.4 4 9.8 5.1 (0.0-10.2) 9.1 (0.0-17.9)
16-18 & LR+ 1 0.1 0 0.0 1 2.4 1.2 (0.0-3.5) 2.4 (0.0-7.0)
6-11 alone 8 1.0 1 2.4 0 0.0 0.7 (0.0-3.1)
6-11 & HR+(exclued 16-18) 2 0.3 0 0.0 2 4.9 2.3 (0.0-5.6) 4.8 (0.0-11.2)
6-11 & other LR+ 1 0.1 1 2.4 0 0.0 1.2 (0.0-3.5)
other HR+ only 52 6.7 9 21.4 15 36.6 26.0 (14.7-35.8) 34.8 (17.5-48.4)
other LR+ only 19 2.5 3 7.1 0 0.0 2.5 (0.0-6.7)
other HR+ & LR+ 3 0.4 1 2.4 2 4.9 3.5 (0.0-7.4) 4.8 (0.0-11.1)
All PAR adjusted by age.
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positivity would not be substantially different.
On the other hand, a more relevant impact on CIN2
and CIN3 reduction is expected: in a large study con-
ducted in the same geographic area [23] more than 70%
CIN2+ was due to HPV16-18. The final consequence of
the differential impact on cytology and histology will be
a dramatic decrease of cytology PPV. This scenario has
already been hypothesized by other authors [24-26]. Our
data bring another small piece of evidence from Italian
screening programs, confirming its likelihood.
The shift to HPV DNA as primary screening test may
change the scenario [25,26], but at the moment in
younger women the results about screening with HPV
test are contradictory [27]. Furthermore the implemen-
tation of a completely new screening algorithm will be a
gradual process. Consequently, we cannot exclude that
the first vaccinated cohorts will be still screened with
Pap-test.
Limits
We tested women who were invited and participated to
cervical cancer screening programs in Rome and south-
ern Italy. Response to organised screening is quite low,
ranging from 25 to 50% in the selected areas; low parti-
cipation may introduce a self-selection bias. Neverthe-
less, active invitation, for the study or for the screening,
is the only mean we had of reducing self-selection bias
in surveys. Previous studies found few socio-economic
differences between participants and not participants
[28,29].
A second limit, due to the nesting of this study into
organised screening programs, is that we could not
include some regions, such as Calabria and Apulia,
because at the time the study started there were no
active programs contacting the whole target population.
We typed only women positive to HR and LR HCII
probes; according to this protocol we may have missed
women who are positive to other HPV types not
included in the probes or samples with very low number
of virus DNA copies. This typing strategy was the same
used in all the pre-vaccination studies sponsored by the
Ministry of Health making the results comparable
[14,15] and in many international studies included in
the largest meta-analysis ever published to date [30].
In this report, the vaccine cross-protection against
HPV strains not present in the vaccine mix was not
taken into consideration. On this issue, only rough esti-
mates can be put forward. Moreover, different defini-
tions of cross-protection values are reported: for
quadrivalent vaccines, cross-protection refers to HPV
31, 33, 45, 52, 58 infection and was estimated to be 25%
[31], while for bivalent vaccines it refers to all non-
vaccine HR types persistent infection (at least for
6 months) and was shown to be 11% [32]. According to
these data, the reduction values reported here would be
increased by 2.3% (25%*9.2%, i.e. the PAR for 31, 33, 45,
52, 58 types) and 2.5% (11%*23%, i.e. the PAR for non-
vaccine HR types), respectively.
Conclusions
The impact of mass vaccination on cytology screening
programs recall rate would be negligible, while probably
its impact on CIN2+ detection rate would be much
stronger. Our data support the hypothesis that the posi-
tive predictive value of Pap test in vaccinated women
would be dramatically lower than in non-vaccinated
women, as argued by several authors.
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